Zimmer Biomet's (ZBH) Hold Rating Reaffirmed at Truist Financial

Key Points

• Truist Financial reaffirmed a hold rating on Zimmer Biomet and lowered its price target to $92 from $98, implying roughly a 12.5% upside from the prior close.
• Zimmer Biomet beat Q1 expectations with adjusted EPS of $2.09 and revenue of about $2.09B, and raised FY‑2026 adjusted EPS guidance to $8.40–$8.55, pointing to stronger demand and margin expansion.
• A sudden CFO departure (effective April 28) and appointment of an interim CFO spooked investors and coincided with a sharp intraday selloff, contributing to the stock's near‑term underperformance.

Zimmer Biomet (NYSE:ZBH - Get Free Report)'s stock had its "hold" rating reaffirmed by stock analysts at Truist Financial in a report released on Wednesday,Benzinga reports. They presently have a $92.00 target price on the medical equipment provider's stock, down from their previous target price of $98.00. Truist Financial's price objective would indicate a potential upside of 12.48% from the company's previous close.

Several other equities research analysts also recently weighed in on the stock. Leerink Partners initiated coverage on shares of Zimmer Biomet in a research note on Monday, April 13th. They set a "hold" rating and a $101.00 target price on the stock. Sanford C. Bernstein raised their price target on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a "market perform" rating in a research report on Friday, January 9th. TD Cowen upgraded shares of Zimmer Biomet from a "hold" rating to a "buy" rating in a research note on Monday, January 26th. Citigroup reiterated a "neutral" rating on shares of Zimmer Biomet in a research note on Wednesday. Finally, UBS Group reiterated a "sell" rating and issued a $89.00 target price on shares of Zimmer Biomet in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $104.14.

Zimmer Biomet Trading Down 1.2%

ZBH traded down $1.01 during mid-day trading on Wednesday, hitting $81.79. 423,755 shares of the stock were exchanged, compared to its average volume of 2,235,936. The firm's fifty day moving average is $93.23 and its two-hundred day moving average is $92.89. Zimmer Biomet has a 1-year low of $80.38 and a 1-year high of $108.29. The company has a market cap of $15.83 billion, a PE ratio of 23.10, a PEG ratio of 1.89 and a beta of 0.61. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.Zimmer Biomet's revenue was up 9.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities analysts forecast that Zimmer Biomet will post 8.39 earnings per share for the current fiscal year.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the firm's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the sale, the senior vice president owned 10,224 shares of the company's stock, valued at approximately $967,803.84. This trade represents a 20.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.28% of the company's stock.

Institutional Trading of Zimmer Biomet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZBH. DV Equities LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $25,000. Key Financial Inc grew its position in shares of Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. raised its stake in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider's stock worth $29,000 after acquiring an additional 116 shares in the last quarter. Monetary Solutions Ltd acquired a new position in Zimmer Biomet in the fourth quarter valued at $30,000. Finally, Root Financial Partners LLC acquired a new position in Zimmer Biomet in the third quarter valued at $31,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Key Stories Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q1 results beat expectations: adjusted EPS $2.09 and revenue ~$2.09B (up ~9.3% y/y); company raised FY‑2026 adjusted EPS guidance to $8.40–$8.55, signaling stronger underlying demand and margin expansion. Read More.
• Neutral Sentiment: Earnings call / transcripts provide color on product momentum, salesforce changes and margin drivers — useful for modeling near-term organic growth and cost outlook. Read More. • Read More.
• Negative Sentiment: Executive turnover spooked investors: CFO Suketu Upadhyay departed effective April 28 and an interim CFO was named — headlines and coverage of leadership exits coincided with a sharp intraday selloff (reports note a plunge to a multi‑year low). Read More. • Read More.
• Negative Sentiment: Despite the beat, shares underperformed peers and dipped in pre‑market trading — suggests investor focus on leadership risk and valuation vs. near‑term volatility rather than the quarter itself. Read More. • Read More.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.